Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.
BACKGROUND
In patients with cirrhosis and spontaneous bacterial peritonitis, renal function frequently becomes impaired. This impairment is probably related to a reduction in effective arterial blood volume and is associated with a high mortality rate. We conducted a study to determine whether plasma volume expansion with intravenous albumin prevents renal impairment and reduces mortality in these patients.


METHODS
We randomly assigned 126 patients with cirrhosis and spontaneous bacterial peritonitis to treatment with intravenous cefotaxime (63 patients) or cefotaxime and intravenous albumin (63 patients). Cefotaxime was given daily in dosages that varied according to the serum creatinine level, and albumin was given at a dose of 1.5 g per kilogram of body weight at the time of diagnosis, followed by 1 g per kilogram on day 3. Renal impairment was defined as nonreversible deterioration of renal function during hospitalization.


RESULTS
The infection resolved in 59 patients in the cefotaxime group (94 percent) and 62 in the cefotaxime-plus-albumin group (98 percent) (P=0.36). Renal impairment developed in 21 patients in the cefotaxime group (33 percent) and 6 in the cefotaxime-plus-albumin group (10 percent) (P=0.002). Eighteen patients (29 percent) in the cefotaxime group died in the hospital, as compared with 6 (10 percent) in the cefotaxime-plus-albumin group (P=0.01); at three months, the mortality rates were 41 percent (a total of 26 deaths) and 22 percent (a total of 14 deaths), respectively (P=0.03). Patients treated with cefotaxime had higher levels of plasma renin activity than those treated with cefotaxime and albumin; patients with renal impairment had the highest values.


CONCLUSIONS
In patients with cirrhosis and spontaneous bacterial peritonitis, treatment with intravenous albumin in addition to an antibiotic reduces the incidence of renal impairment and death in comparison with treatment with an antibiotic alone.
Sort
P
P
Liver Unit, Institut de Malalties Digestives, Hospital Clínic, Barcelona, Catalunya, Spain.
Navasa
M
M
Arroyo
V
V
Aldeguer
X
X
Planas
R
R
Ruiz-del-Arbol
L
L
Castells
L
L
Vargas
V
V
Soriano
G
G
Guevara
M
M
Ginès
P
P
Rodés
J
J
D000328:Adult; D000368:Aged; D000418:Albumins / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000097:blood / Q000209:etiology / Q000628:therapy*; D002439:Cefotaxime / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007674:Kidney Diseases / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D008103:Liver Cirrhosis / Q000150:complications* / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010538:Peritonitis / Q000097:blood / Q000209:etiology / Q000628:therapy*; D010953:Plasma Volume; D012083:Renin / Q000097:blood
D000418:Albumins; D002511:Cephalosporins; D012083:Renin; D002439:Cefotaxime